206 related articles for article (PubMed ID: 20305034)
21. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial.
Engert A; Haverkamp H; Kobe C; Markova J; Renner C; Ho A; Zijlstra J; Král Z; Fuchs M; Hallek M; Kanz L; Döhner H; Dörken B; Engel N; Topp M; Klutmann S; Amthauer H; Bockisch A; Kluge R; Kratochwil C; Schober O; Greil R; Andreesen R; Kneba M; Pfreundschuh M; Stein H; Eich HT; Müller RP; Dietlein M; Borchmann P; Diehl V; ; ;
Lancet; 2012 May; 379(9828):1791-9. PubMed ID: 22480758
[TBL] [Abstract][Full Text] [Related]
22. ABVD and BEACOPP regimens' effects on fertility in young males with Hodgkin lymphoma.
Amin MSA; Brunckhorst O; Scott C; Wrench D; Gleeson M; Kazmi M; Ahmed K
Clin Transl Oncol; 2021 Jun; 23(6):1067-1077. PubMed ID: 32944834
[TBL] [Abstract][Full Text] [Related]
23. Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma.
Avigdor A; Bulvik S; Levi I; Dann EJ; Shemtov N; Perez-Avraham G; Shimoni A; Nagler A; Ben-Bassat I; Polliack A
Ann Oncol; 2010 Jan; 21(1):126-32. PubMed ID: 19608615
[TBL] [Abstract][Full Text] [Related]
24. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
[TBL] [Abstract][Full Text] [Related]
25. Early intensification treatment approach in advanced-stage Hodgkin lymphoma.
Borchmann P
Hematol Oncol Clin North Am; 2014 Feb; 28(1):65-74. PubMed ID: 24287068
[TBL] [Abstract][Full Text] [Related]
26. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
Engert A; Diehl V; Franklin J; Lohri A; Dörken B; Ludwig WD; Koch P; Hänel M; Pfreundschuh M; Wilhelm M; Trümper L; Aulitzky WE; Bentz M; Rummel M; Sezer O; Müller-Hermelink HK; Hasenclever D; Löffler M
J Clin Oncol; 2009 Sep; 27(27):4548-54. PubMed ID: 19704068
[TBL] [Abstract][Full Text] [Related]
27. Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma.
Bauer K; Skoetz N; Monsef I; Engert A; Brillant C
Cochrane Database Syst Rev; 2011 Aug; (8):CD007941. PubMed ID: 21833963
[TBL] [Abstract][Full Text] [Related]
28. Multicentre phase II study of the baseline BEACOPP regimen for patients with advanced-stage Hodgkin's lymphoma.
Niitsu N; Okamoto M; Tomita N; Aoki S; Tamaru J; Miura I; Hirano M
Leuk Lymphoma; 2006 Sep; 47(9):1908-14. PubMed ID: 17065005
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of ovarian reserve before and after chemotherapy.
Berjeb KK; Debbabi L; Braham M; Zemni Z; Chtourou S; Hannachi H; Hamdoun M; Ayadi M; Kacem K; Zhioua F; Fadhlaoui A; Bahri O; Chakroun N
J Gynecol Obstet Hum Reprod; 2021 May; 50(5):102035. PubMed ID: 33307239
[TBL] [Abstract][Full Text] [Related]
30. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.
Federico M; Luminari S; Iannitto E; Polimeno G; Marcheselli L; Montanini A; La Sala A; Merli F; Stelitano C; Pozzi S; Scalone R; Di Renzo N; Musto P; Baldini L; Cervetti G; Angrilli F; Mazza P; Brugiatelli M; Gobbi PG;
J Clin Oncol; 2009 Feb; 27(5):805-11. PubMed ID: 19124807
[TBL] [Abstract][Full Text] [Related]
31. A 10-year experience with treatment of high and standard risk Hodgkin disease: six cycles of tailored BEACOPP, with interim scintigraphy, are effective and female fertility is preserved.
Dann EJ; Blumenfeld Z; Bar-Shalom R; Avivi I; Ben-Shachar M; Goor O; Libster D; Gaitini D; Rowe JM; Epelbaum R
Am J Hematol; 2012 Jan; 87(1):32-6. PubMed ID: 21956220
[TBL] [Abstract][Full Text] [Related]
32. Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?
Diehl V; Fuchs M;
Transfus Apher Sci; 2007 Aug; 37(1):37-41. PubMed ID: 17714996
[TBL] [Abstract][Full Text] [Related]
33. High-Risk, Advanced-Stage Hodgkin Lymphoma: The Impact of Combined Escalated BEACOPP and ABVD Treatment in Patients Who Rapidly Achieve Metabolic Complete Remission on Interim FDG-PET/CT Scan.
Kedmi M; Apel A; Davidson T; Levi I; Dann EJ; Polliack A; Ben-Bassat I; Nagler A; Avigdor A
Acta Haematol; 2016; 135(3):156-61. PubMed ID: 26588173
[TBL] [Abstract][Full Text] [Related]
34. Modified escalated BEACOPP as salvage chemotherapy in classic Hodgkin lymphoma.
Fesler MJ; Nguyen NC; Petruska PJ
Int J Hematol; 2010 Jul; 92(1):211-3. PubMed ID: 20582576
[No Abstract] [Full Text] [Related]
35. Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP.
Jachimowicz RD; Klapper W; Glehr G; Müller H; Haverkamp H; Thorns C; Hansmann ML; Möller P; Stein H; Rehberg T; von Tresckow B; Reinhardt HC; Borchmann P; Chan FC; Spang R; Scott DW; Engert A; Steidl C; Altenbuchinger M; Rosenwald A
Leukemia; 2021 Dec; 35(12):3589-3593. PubMed ID: 34112956
[No Abstract] [Full Text] [Related]
36. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
Viviani S; Zinzani PL; Rambaldi A; Brusamolino E; Levis A; Bonfante V; Vitolo U; Pulsoni A; Liberati AM; Specchia G; Valagussa P; Rossi A; Zaja F; Pogliani EM; Pregno P; Gotti M; Gallamini A; Rota Scalabrini D; Bonadonna G; Gianni AM; ; ;
N Engl J Med; 2011 Jul; 365(3):203-12. PubMed ID: 21774708
[TBL] [Abstract][Full Text] [Related]
37. Prophylactic use of filgrastim with ABVD and BEACOPP chemotherapy regimens for Hodgkin lymphoma.
Wedgwood A; Younes A
Clin Lymphoma Myeloma; 2007 Dec; 8 Suppl 2():S63-6. PubMed ID: 18284718
[TBL] [Abstract][Full Text] [Related]
38. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
[TBL] [Abstract][Full Text] [Related]
39. Escalated BEACOPP in advanced Hodgkin's lymphoma.
Casasnovas O; Coiffier B
Lancet; 2012 May; 379(9828):1767-8. PubMed ID: 22480757
[No Abstract] [Full Text] [Related]
40. Long-Term Results of the HD2000 Trial Comparing ABVD Versus BEACOPP Versus COPP-EBV-CAD in Untreated Patients With Advanced Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
Merli F; Luminari S; Gobbi PG; Cascavilla N; Mammi C; Ilariucci F; Stelitano C; Musso M; Baldini L; Galimberti S; Angrilli F; Polimeno G; Scalzulli PR; Ferrari A; Marcheselli L; Federico M
J Clin Oncol; 2016 Apr; 34(11):1175-81. PubMed ID: 26712220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
